Chae Sungjoon has officially filed a Form 3, confirming his role as Co-Chief Executive Officer at Apimeds Pharmaceuticals US, Inc. This filing is significant as it underscores the leadership structure within the company, which is crucial for its strategic direction and operations.

Apimeds Pharmaceuticals US, Inc. operates within the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) of 2834. The company is based in Matawan, New Jersey, and is incorporated in Delaware. The recent filing, dated November 5, 2026, is part of a series of disclosures that help maintain transparency in corporate governance.

The filing states that Chae Sungjoon is an officer of the company, specifically holding the title of Co-Chief Executive Officer. It does not indicate any ownership of securities or a directorship role. The document notes that he signed the filing on the same day it was submitted, affirming his position within the company.

This update may affect various stakeholders, including employees, investors, and partners of Apimeds Pharmaceuticals, as leadership changes can influence company policies and strategic initiatives. However, the filing does not mention any competitors or specific impacts on the industry at large.

Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this leadership confirmation.